We are live on ! Find out more
NRXPW

NRX Pharmaceuticals Warrant
NRXPW

Delisted

NRXPW was delisted on the 22nd of May, 2026.

Back to rankings

3 hedge funds and large institutions have $2.99K invested in NRX Pharmaceuticals Warrant in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% less ownership

Funds ownership: 0.05% → 0.03% (-0.02%)

2% less capital invested

Capital invested by funds: $3.04K → $2.99K (-$47)

40% less funds holding

Funds holding: 5 → 3 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$625
2
WAM
Wolverine Asset Management
Illinois
-$460
3
YCM
Yakira Capital Management
Connecticut
-$166
4
Bank of America
Bank of America
North Carolina
-$48
Name Holding Trade Value Shares
Change 		Change in
Stake
YCM
1
Yakira Capital Management
Connecticut
$2K -$166 -1,720 -10%
WAM
2
Wolverine Asset Management
Illinois
$993 -$460 -4,769 -38%
TRCT
3
Tower Research Capital (TRC)
New York
$2 – – –
UBS Group
4
UBS Group
Switzerland
– -$625 -7,812 Closed
Bank of America
5
Bank of America
North Carolina
– -$48 -600 Closed

NRXPW Hedge Fund Activity: Q4 2023 in Review

3 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q4 2023, worth a combined $2.99K — down 1.5% from $3.04K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of NRXPW and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was UBS Group, exiting entirely with an estimated $625 sold.

  • 3 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q4 2023, down from 5 in Q3 2023.
  • Funds reported $2.99K of NRX Pharmaceuticals Warrant stock for Q4 2023, down 1.5% quarter-over-quarter.
  • 0 funds opened new NRX Pharmaceuticals Warrant positions in Q4 2023 and 2 closed out, a net change of -2 holders.
  • The largest NRX Pharmaceuticals Warrant seller in Q4 2023 was UBS Group, an estimated $625 sold.

Based on aggregated 13F filings for Q4 2023.